St Jude Medical News
TheStreet highlights 5 stocks pushing the health services industry lower today.
With its stock price already doubled in value over the last 12 months, is it time to back away from shares of Boston Scientific (BSX)? Cowen & Co. analyst Joshua Jennings doesn't think so. In a note published today, Jennings upgraded the medical device maker to Outperform for the first time since initiating coverage in 2011 at Market Perform, and set a price target of $14 a share, citing key new devices. Boston has been on a roll for much of 2013, recovering from an eight-year funk caused by safety issues and recalls, a weak market for implantable defibrillators used to treat irregular heartbeats and the pressure put on medical device makers by the recession here and in Europe.
St. Jude Medical's a leader in neuromodulation, but with rivals crowding out the space, it's looking to move into the next generation of devices.
Johnson & Johnson's and St. Jude's turf war for dominance in treating atrial fibrillation is shifting to next-generation technologies. This is creating opportunities for certain companies as market demand climbs.
A wave of innovation is hitting the implantable pacemaker industry, which could have game-changing implications for Medtronic, St. Jude, and Boston Scientific.
St. Jude Medical Begins US Study to Evaluate Combination of Peripheral Nerve Field Stimulation and Spinal Cord Stimulation for Chronic Low Back and Leg Painnoodls Dec 4
ST. PAUL, Minn.--(BUSINESS WIRE)--Dec. 4, 2013-- St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, has launched a clinical study to evaluate the combination of peripheral nerve field ...
Donald Zurbay At CRM, we have a leadership with our Quadripolar Lead system. We are certainly the only company that has this system in the US. We are on our second generation O-US, and so, when we look ...
One of the fastest growing areas in cardiac treatment is atrial fibrillation. That growth is capturing the attention of major medical device companies like St. Jude (STJ), who are eagerly acquiring next generation technology.
Cardiac and vascular medical giant Medtronic ( MDT ) reported solid fiscal second quarter results. Revenue advanced 3.3% on a constant-currency basis, while non-GAAP diluted earnings per share jumped to ...
St. Jude Medical Launches US Study of New Prodigy Neurostimulator to Evaluate Burst Stimulation Technology for Chronic Painnoodls Dec 3
ST. PAUL, Minn.--(BUSINESS WIRE)--Dec. 3, 2013-- St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, has initiated a clinical study of the Prodigy™ neurostimulator, the first spinal cord ...
Shares of St. Jude Medical started escalating following its strong third quarter results on Oct 16 and higher earnings guidance
TheStreet highlights 5 stocks pushing the health services industry higher today.
We have reiterated our Outperform recommendation for Greatbatch.